Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Alaaeldin Abdelsalam Dawood  (Dawood AA) 1 Article
Others
Factors Associated with Improved Glycemic Control by Direct-Acting Antiviral Agent Treatment in Egyptian Type 2 Diabetes Mellitus Patients with Chronic Hepatitis C Genotype 4
Alaaeldin Abdelsalam Dawood, Mohamed Zakarya Nooh, Ayman Abdelhaleem Elgamal
Diabetes Metab J. 2017;41(4):316-321.   Published online August 22, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.4.316
  • 3,704 View
  • 33 Download
  • 42 Web of Science
  • 43 Crossref
AbstractAbstract PDFPubReader   
Background

The association of chronic hepatitis C virus (HCV) infection with type 2 diabetes mellitus (T2DM) was first reported in 1994. Little is known about the effect of direct-acting antiviral agents (DAAs) on glycemic control in T2DM patients. The aim of the present study was to evaluate the factors associated with improved glycemic control (IGC) by DAA treatment in Egyptian T2DM patients with chronic HCV genotype 4 infection.

Methods

This study included 460 T2DM patients with chronic HCV genotype 4 infection. Four hundred patients received DAAs and 60 patients did not receive DAAs. Patients with sustained virological response after 3 months of DAAs (378 patients) were allocated into two groups: first group included 292 patients (77.2%) with IGC and second group included 86 patients (22.8%) with non-improved glycemic control (NIGC).

Results

In IGC group, 78 patients (26.7%) needed to decrease the dose of antidiabetic treatment. There were no significant differences between IGC and NIGC groups as regards age, sex, and body mass index. The percentage of patients with positive family history of T2DM, those with Child B class and duration of T2DM were significantly higher in NIGC group compared to IGC.

Conclusion

Diabetic patients receiving DAAs should be closely monitored for reduction of antidiabetic drugs especially insulin and sulfonylurea to avoid hypoglycemic events. Improvement of glycemic control with DAAs is more in patients without family history of T2DM, short duration of diabetes mellitus, and mild liver disease.

Citations

Citations to this article as recorded by  
  • Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review
    Annalisa Cespiati, Inês Coelho Rodrigues, Inês Santos, Sara Policarpo, Sofia Carvalhana, Anna Ludovica Fracanzani, Helena Cortez‐Pinto
    Liver International.2024;[Epub]     CrossRef
  • Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients
    Doaa Mohamed Abdelnajid, Ahmed Y. Elmowafy, Lionel Rostaing, Marwa T. Elrakaiby
    Medicine.2023; 102(28): e34125.     CrossRef
  • Hypoglycemia associated with direct‐acting anti‐hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)
    Yu Zhou, Wenhuo Xie, Chenhua Zheng, Libin Liu, Zhou Chen, Xiaolu Wang
    Clinical Endocrinology.2022; 96(5): 690.     CrossRef
  • Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response
    Sara Cuesta-Sancho, Mercedes Márquez-Coello, Francisco Illanes-Álvarez, Denisse Márquez-Ruiz, Ana Arizcorreta, Fátima Galán-Sánchez, Natalia Montiel, Manuel Rodriguez-Iglesias, José-Antonio Girón-González
    World Journal of Hepatology.2022; 14(1): 62.     CrossRef
  • Therapy of Chronic Viral Hepatitis: The Light at the End of the Tunnel?
    Giorgio Maria Saracco, Alfredo Marzano, Mario Rizzetto
    Biomedicines.2022; 10(3): 534.     CrossRef
  • Hépatite B et C: une mise à jour sur lʼhépatite virale chronique
    Marie Ongaro, Francesco Negro
    Schweizer Gastroenterologie.2022; 3(1): 19.     CrossRef
  • Effect of achieving sustained virological response with direct-acting antiviral agents on glycemic control in diabetic patients with chronic hepatitis C infection
    Mohamed El-Kassas, Runia El-Folly, Maram Aboromia, Heba Aly, Mohamed Bahgat, Mostafa Hamed
    Egyptian Liver Journal.2022;[Epub]     CrossRef
  • Hepatitis C virus infection and diabetes: A complex bidirectional relationship
    Stefano Ciardullo, Alessandro Mantovani, Antonio Ciaccio, Marco Carbone, Pietro Invernizzi, Gianluca Perseghin
    Diabetes Research and Clinical Practice.2022; 187: 109870.     CrossRef
  • Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?
    Rasha Youssef Hagag, Ahmed Fawzy Selim, Omneya Darrag, Hassan Zied, Mohamed Sabry Aboelnasr
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 1261.     CrossRef
  • Metabolic changes in chronic hepatitis C patients receiving direct acting antivirals
    Nehal K. Abdel Fattah, Sara M. Shaheen, Osama A. Ahmed, Kadry Elsaeed, Nagwa A. Sabri
    F1000Research.2022; 11: 649.     CrossRef
  • Hepatitis C virus, insulin resistance, and diabetes: A review
    Nabeel Alzahrani
    Microbiology and Immunology.2022; 66(10): 453.     CrossRef
  • The Extent of Insulin Resistance in Patients That Cleared Viral Hepatitis C Infection and the Role of Pre-Existent Type 2 Diabetes Mellitus: A Meta-Analysis
    Marian-Sorin Popescu, Andrei Ioan Drocas, Andrei Osman, Dan-Mihai Firu, Vlad Pădureanu, Cristina Maria Mărginean, Daniel-Cristian Pîrvu, Radu Mitruț, Dragoș Nicolae Mărgăritescu, Antonia Radu, Daniela Calina, Anca Oana Docea, Paul Mitruț
    Reports.2022; 5(4): 42.     CrossRef
  • Global longitudinal strain as a predictor of short-term effect of oral antiviral regimens on myocardium in Egyptian patients with chronic viral hepatitis C
    Hazem Mohammad-Ali Farrag, Mina Samir Monir, Wael Soliman Abdel-Dayem, Hisham Abdel-Haleem Ali, Alaa Mohammad Ibrahim
    The Egyptian Heart Journal.2021;[Epub]     CrossRef
  • Residual risk of liver disease after hepatitis C virus eradication
    Francesco Negro
    Journal of Hepatology.2021; 74(4): 952.     CrossRef
  • Extrahepatic Manifestations of Chronic HCV Infection
    Dan L. Longo, Patrice Cacoub, David Saadoun
    New England Journal of Medicine.2021; 384(11): 1038.     CrossRef
  • Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents
    Sergio Estefan, Carlos Eduardo Brandão-Melo, Cintia Marques dos Santos Silva, Danilo Cosme Klein Gomes, Paula Cardoso, Marcia Helena S. Costa
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • Current situation of viral hepatitis in Egypt
    Ashraf Elbahrawy, Marwa K. Ibrahim, Ahmed Eliwa, Mohamed Alboraie, Ali Madian, Hussein Hassan Aly
    Microbiology and Immunology.2021; 65(9): 352.     CrossRef
  • The impact of direct-acting antiviral treatment on glycemic homeostasis in patients with chronic hepatitis C
    Marco SACCO, Giorgio M. SARACCO
    Minerva Gastroenterology.2021;[Epub]     CrossRef
  • The impact of HCV eradication on hyperglycemia, insulin resistance, cytokine production, and insulin receptor substrate-1 and 2 expression in patients with HCV infection
    Basant Mahmoud, Adel Abdel Moneim, Doaa Mabrouk
    Clinical and Experimental Medicine.2021; 22(4): 583.     CrossRef
  • Systematic review: chronic viral hepatitis and metabolic derangement
    Chia‐Chi Wang, Pin‐Nan Cheng, Jia‐Horng Kao
    Alimentary Pharmacology & Therapeutics.2020; 51(2): 216.     CrossRef
  • Effect of treatment with direct antiviral agents (DAAs) on glycemic control in patients with type 2 diabetes mellitus & hepatitis C virus genotype 4
    Hassan Yousef Zied, Nashwa Mohamed Abo Alnasr, Amal Said El-Bendary, Sherief Abd-Elsalam, Rasha Youssef Hagag
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(4): 679.     CrossRef
  • Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus
    Pradeep Kumar Mada, Matthew E. Malus, Arvin Parvathaneni, Bing Chen, Gabriel Castano, Sharon Adley, Maureen Moore, Michinari Hieda, Mohammed J. Alam, Mark Feldman, John William King
    International Journal of Hepatology.2020; 2020: 1.     CrossRef
  • Cirrhosis and insulin resistance: current knowledge, pathophysiological mechanisms, complications and potential treatments
    Frédéric Clarembeau, Georgia Bale, Nicolas Lanthier
    Clinical Science.2020; 134(16): 2117.     CrossRef
  • Treatment of Hepatitis C Virus and Long-Term Effect on Glycemic Control
    Jennifer Andres, Michael Barros, Michael Arutunian, Huaqing Zhao
    Journal of Managed Care & Specialty Pharmacy.2020; 26(6): 775.     CrossRef
  • Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy
    Francesco Negro
    Cold Spring Harbor Perspectives in Medicine.2020; 10(4): a036921.     CrossRef
  • The Effect of Viral Clearance Achieved by Direct-Acting Antiviral Agents on Hepatitis C Virus Positive Patients with Type 2 Diabetes Mellitus: A Word of Caution after the Initial Enthusiasm
    Davide Giuseppe Ribaldone, Marco Sacco, Giorgio Maria Saracco
    Journal of Clinical Medicine.2020; 9(2): 563.     CrossRef
  • Metabolic and renal changes in patients with chronic hepatitis C infection after hepatitis C virus clearance by direct‐acting antivirals
    Riccardo Nevola, Luca Rinaldi, Letizia Zeni, Ferdinando C Sasso, Pia C Pafundi, Barbara Guerrera, Aldo Marrone, Mauro Giordano, Luigi E Adinolfi
    JGH Open.2020; 4(4): 713.     CrossRef
  • Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control
    Mohamed Mohei El Badry, Doaa Abdelhady Ali, Noha Hamdy Eltaweel, Marwa A. Abdel-Wahed
    Egyptian Liver Journal.2020;[Epub]     CrossRef
  • Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis
    Kamolyut Lapumnuaypol, David Pisarcik, Prapaipan Putthapiban, Weera Sukhumthammarat, Karn Wijarnpreecha, Charat Thongprayoon, Patompong Ungprasert
    Indian Journal of Medical Research.2020; 152(6): 562.     CrossRef
  • Fisiopatología de la hepatitis C y diabetes mellitus. Hacia la cura de dos epidemias en el siglo XXI
    Harold Ariel Muñoz Díaz, Adán José Lúquez Mindiola, Andrés José Gómez Aldana
    Revista Colombiana de Gastroenterología.2019; 34(3): 277.     CrossRef
  • Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients
    Giacomo Gastaldi, Diana Gomes, Philippe Schneiter, Xavier Montet, Luc Tappy, Sophie Clément, Francesco Negro, Jee-Fu Huang
    PLOS ONE.2019; 14(6): e0217751.     CrossRef
  • The impact of a successful treatment of hepatitis C virus on glyco-metabolic control in diabetic patients: a systematic review and meta-analysis
    Carla Carnovale, Marco Pozzi, Alice Dassano, Francesca D’Addio, Marta Gentili, Carlo Magni, Emilio Clementi, Sonia Radice, Paolo Fiorina
    Acta Diabetologica.2019; 56(3): 341.     CrossRef
  • Sustained Improvement in Type 2 Diabetes Mellitus is Common After Treatment of Hepatitis C Virus With Direct-acting Antiviral Therapy
    Amir Gilad, Zachary P. Fricker, Adam Hsieh, Dylan D. Thomas, Toni Zahorian, David P. Nunes
    Journal of Clinical Gastroenterology.2019; 53(8): 616.     CrossRef
  • Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure
    Teegan R. Lim, Jonathan M. Hazlehurst, Andrei I. Oprescu, Matthew J. Armstrong, Sewa F. Abdullah, Nigel P. Davies, Robert Flintham, Peter Balfe, David J. Mutimer, Jane A. McKeating, Jeremy W. Tomlinson
    Clinical Endocrinology.2019; 90(3): 440.     CrossRef
  • Direct‐acting antivirals for HCV treatment in older patients: A systematic review and meta‐analysis
    Rosanna Villani, Matteo Monami, Francesca Di Cosimo, Gilda Fioravanti, Edoardo Mannucci, Gianluigi Vendemiale, Gaetano Serviddio
    Journal of Viral Hepatitis.2019; 26(11): 1249.     CrossRef
  • Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
    Sylvia Drazilova, Jakub Gazda, Martin Janicko, Peter Jarcuska
    Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1.     CrossRef
  • The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease
    Zobair Younossi, Georgios Papatheodoridis, Patrice Cacoub, Francesco Negro, Heiner Wedemeyer, Linda Henry, Angelos Hatzakis
    Journal of Viral Hepatitis.2018; 25(S3): 6.     CrossRef
  • Poor glycemic control and abrupt onset of diabetes in HCV patients receiving direct-acting antiviral drugs: case series
    Braira Wahid, Muhammad Wasim, Komal Saleem, Muhammad Waqar, Khansa Wahid, Manzoor Hussain, Muhammad Idrees
    Future Virology.2018; 13(8): 525.     CrossRef
  • Risk of diabetes in HIV‐infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort
    A. Provoost, M. Dramé, L. Cotte, L. Cuzin, R. Garraffo, D. Rey, F. Raffi, I. Poizot‐Martin, P. Pugliese, F. Bani‐Sadr
    Alimentary Pharmacology & Therapeutics.2018; 48(3): 281.     CrossRef
  • The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C
    Luigi Elio Adinolfi, Luca Rinaldi, Aldo Marrone, Mauro Giordano
    Expert Review of Anti-infective Therapy.2018; 16(8): 595.     CrossRef
  • Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals
    Sylvia Drazilova, Martin Janicko, Lubomir Skladany, Pavol Kristian, Marian Oltman, Maria Szantova, Dusan Krkoska, Eva Mazuchova, Lubica Piesecka, Veronika Vahalova, Marek Rac, Ivan Schreter, Ladislav Virag, Tomas Koller, Adriana Liptakova, Miriam Ondrasov
    Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1.     CrossRef
  • INSULIN RESISTANCE REDUCTION AFTER SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT ACTING ANTIVIRAL:NOT EVERY POPULATION IMPROVES
    Vanessa Gutierrez de ANDRADE, Fábio da Silva YAMASHIRO, Cássio Vieira OLIVEIRA, Alecsandro MOREIRA, Fernanda Cristina WINCKLER, Giovanni Faria SILVA
    Arquivos de Gastroenterologia.2018; 55(3): 274.     CrossRef
  • Expert Opinion on Managing Chronic HCV Infection in Patients with Type 2 Diabetes Mellitus
    Luigi Elio Adinolf, Ira Jacobson, Mark Bondin, Patrice Cacoub
    Antiviral Therapy.2018; 23(1_suppl): 11.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal